Related Experiment Video

Updated: Aug 19, 2026

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings
10:46

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings

Published on: September 1, 2023

Serum lipid levels during carbamazepine therapy in epileptic children

T Mahmoudian1, R Iranpour, N Messri

  • 1Department of Child Neurology, Medical University of Isfahan, Isfahan, Iran. t_mahmoudian@med.mui.ac.ir

Epilepsy & Behavior : E&B
|February 16, 2005
PubMed

Insights

Carbamazepine therapy in epileptic children significantly increases harmful lipid levels, potentially raising atherosclerosis risk. Further research is needed to understand these effects on pediatric cardiovascular health.

Area of Science:

  • Pediatric Neurology
  • Clinical Chemistry
  • Cardiovascular Risk Assessment

Background:

  • Epilepsy is a common neurological disorder in children.
  • Carbamazepine is a widely used antiepileptic drug.
  • Altered lipid profiles are associated with cardiovascular disease.

Purpose of the Study:

  • To investigate the impact of carbamazepine therapy on serum lipid profiles in epileptic children.
  • To assess potential cardiovascular risks associated with carbamazepine treatment in pediatric patients.

Main Methods:

  • A cohort of 30 epileptic children (30 months to 14 years) was studied.
  • Serum lipid levels (total cholesterol, LDL, VLDL, triglycerides, HDL) were measured at baseline and after three months of carbamazepine treatment.
  • Carbamazepine dosage was initiated at 10 mg/kg/day.

Main Results:

  • Significant increases in mean total cholesterol, low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), and triglyceride levels were observed (P < 0.05).
  • Mean high-density lipoprotein (HDL) levels did not show a statistically significant change.
  • The observed alterations suggest a potential pro-atherogenic shift in lipid profiles.

Conclusions:

  • Carbamazepine therapy in children with epilepsy can adversely affect serum lipid profiles.
  • These lipid profile changes may increase the long-term risk of atherosclerosis in pediatric patients.
  • Monitoring lipid levels during carbamazepine treatment is advisable for early detection of cardiovascular risk.

More Related Videos

Lipidomics and Transcriptomics in Neurological Diseases09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.